Jubilant Pharmova reported strong Q2 FY26 and H1 FY26 results, highlighted by a 12% YoY revenue increase in Q2 to ₹1,966 Cr. and a 13% YoY EBITDA increase to ₹351 Cr. The company saw growth in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, and CRDMO businesses. The launch of the new CDMO Sterile Injectables line at Spokane is underway.
Financial Performance Highlights
Jubilant Pharmova announced its results for Q2 and H1 FY26, demonstrating substantial growth and progress towards its Vision 2030. Key highlights include:
- Revenue: Q2 FY26 revenue reached ₹1,966 Cr, a 12% YoY increase. H1 FY26 revenue was ₹3,867 Cr, up 11% YoY.
- EBITDA: Q2 FY26 EBITDA grew by 13% YoY to ₹351 Cr. H1 FY26 EBITDA increased by 13% YoY to ₹653 Cr.
- Normalized PAT: Q2 FY26 normalized PAT increased by 21% to ₹124 Cr. H1 FY26 normalized PAT rose by 32% to ₹227 Cr.
Segmental Performance
Radiopharma
Q2 FY26 revenue grew by 16% YoY to ₹291 Cr, with EBITDA increasing by 6% YoY to ₹127 Cr. Expansion of the Ruby-Fill® install base is driving growth. The company is progressing with plans to introduce new PET and SPECT imaging products from FY27 to FY29.
Allergy Immunotherapy
Q2 FY26 revenues increased by 14% to ₹194 Cr, driven by growth in the U.S. market. EBITDA surged by 65% to ₹76 Cr, with margins improving significantly.
CDMO Sterile Injectables
Q2 FY26 revenue grew by 30% to ₹393 Cr, fueled by increased sales volume and incremental revenue from the new Line 3 in Spokane. EBITDA increased by 6% to ₹94 Cr.
CRDMO
The Drug Discovery business saw revenue growth of 7% to ₹162 Cr. API business revenue grew by 8% to ₹137 Cr.
Strategic Developments
The company successfully launched a new sterile fill and finish line, the third line at its Spokane Manufacturing Facility, representing a total investment of US $132 million. The sale of the API business to Jubilant Biosys Limited has been completed.
Source: BSE